Aktie 603439 GUIZHOU SANLI PHARMACEUTICAL CO.,LTD
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen GuiZhou SanLi Pharmaceutical Co.,Ltd

Aktien

603439

CNE1000040B4

603439

Schlusskurs Shanghai S.E.
Andere Börsenplätze
 00:00:00 15.05.2024 		% 5 Tage % 1. Jan.
16,09 CNY -2,66 % Intraday Chart für GuiZhou SanLi Pharmaceutical Co.,Ltd +0,12 % -14,78 %
26.04. Guizhou Sanli Pharmaceutical Co.,Ltd meldet Ergebnis für das erste Quartal zum 31. März 2024 CI
26.04. Guizhou Sanli Pharmaceutical Co.,Ltd berichtet über die Ergebnisse für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024
Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
Tranche Update on Guizhou Sanli Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on November 4, 2023.
Guizhou Sanli Pharmaceutical Co.,Ltd's Equity Buyback announced on November 4, 2023, has closed with 1,550,900 shares, representing 0.38% for CNY 29.99 million.
Guizhou Sanli Pharmaceutical Co.,Ltd announces an Equity Buyback for CNY 40 million worth of its shares.
Guizhou Sanli Pharmaceutical Co.,Ltd authorizes a Buyback Plan.
Guizhou Sanli Pharmaceutical Co.,Ltd completed the acquisition of 50.26% stake in Guizhou Hanfang Pharmaceutical Co., Ltd. from Gui'an New District Shunqi Commercial Operation Management Center (Limited Partnership) and Sheng Yongjian.
Shanghai Guosheng Haitong Private Enterprise High-Quality Development Private Investment Fund and Shanghai Guosheng Capital Management Co., Ltd. completed the acquisition of 5.0017% stake in Guizhou Sanli Pharmaceutical Co.,Ltd(SHSE:603439) from Wang Huiying.
Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023
Guizhou Sanli Pharmaceutical Co.,Ltd agreed to acquire a stake in Guizhou Hanfang Pharmaceutical Co., Ltd. from Gui'an New District Shunqi Commercial Operation Management Center (Limited Partnership) and Sheng Yongjian
Guizhou Sanli Pharma Plans Acquisition for CNY 499.6 Million
Guizhou Sanli Pharmaceutical Co.,Ltd(XSSC:603439) added to S&P Global BMI Index
Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
Shanghai Guosheng Haitong Private Enterprise High-Quality Development Private Investment Fund and Shanghai Guosheng Capital Management Co., Ltd. entered into 5.0017% stake in Guizhou Sanli Pharmaceutical Co.,Ltd from Wang Huiying for CNY 322.875 million.
GuiZhou SanLi Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
Certain A Shares of GuiZhou SanLi Pharmaceutical Co.,LTD. are subject to a Lock-Up Agreement Ending on 28-APR-2023.
GuiZhou SanLi Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022
Guizhou Sanli Pharma Sees Up to 42.5% Jump in 2022 Profit
Guizhou Sanli Pharma Elects Vice Chairman
GuiZhou SanLi Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 603439 Aktie
  4. Nachrichten GuiZhou SanLi Pharmaceutical Co.,Ltd
  5. Andere Sprachen